For COVID-19 and vaccination updates, view our information for the community. If you're experiencing symptoms, call your primary care provider.
A Randomized, Double-Blind, Placebo-Controlled Phase II Study of Oxybutynin versus Placebo for Treatment of Hot Flashes in Men Receiving Androgen Deprivation Therapy
To test whether a low or high dose of oxybutynin can reduce hot flashes.
DiagnosisHormone therapy treatments for your prostate cancer can cause side effects such as hot flashes.
Men receiving androgen deprivation therapy (hormone therapy)
Group 1: Patients will take oxybutynin 2.5 ml two times a day for up to six weeks.
Group 2: Patients will take placebo 2.5 ml two times a day for up to six weeks.
Group 3: Patients will take oxybutynin 5.0 ml two times a day for up to six weeks.
Group 4: Patients will take placebo 5.0 ml two times a day for up to six weeks.
Patients will also complete questionnaires before you start study treatment, daily during treatment, and at the end of treatment.
For more information, visit Clinicaltrials.gov